Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant WNV-HCD86
- Development stage
- Unknown
- Lead developer
- Hubei Cancer Hospital
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intravenous
01
Overview
Recombinant WNV-HCD86 is an investigational oncolytic immunotherapy consisting of a recombinant West Nile Virus (WNV) engineered to express the human costimulatory molecule CD86 (B7-2). Developed by Hubei Cancer Hospital, this agent is designed to selectively infect and lyse tumor cells (oncolysis) while simultaneously stimulating a systemic anti-tumor immune response. The expression of CD86 within the tumor microenvironment provides critical costimulatory signals to T-cells by binding to the CD28 receptor, potentially overcoming local immunosuppression and promoting the activation of tumor-specific lymphocytes. It is currently being evaluated in Phase 1/2 clinical trials in China for the treatment of various advanced, refractory solid tumors, including laryngeal, lung, liver, breast, and colorectal cancers.
- Other names
- recombinant West Nile Virus expressing human CD86WNV-hCD86WNV-hCD-86WNV-hCD 86
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on recombinant WNV-HCD86.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant WNV-HCD86.